NASDAQ:PRTA - Prothena Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$12.16 +0.20 (+1.67 %)
(As of 01/17/2019 10:54 AM ET)
Previous Close$11.96
Today's Range$11.91 - $12.25
52-Week Range$8.63 - $46.14
Volume37,427 shs
Average Volume470,360 shs
Market Capitalization$479.96 million
P/E Ratio-2.99
Dividend YieldN/A
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases in the neuroscience and orphan categories. The company is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a monoclonal antibody that is under preclinical development for the treatment of ATTR Amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, chronic traumatic encephalopathy, and other tauopathies; Aß, or Amyloid Beta for the treatment of Alzheimer's disease; ALECT2 for ALECT2 amyloidosis; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and Sortilin for frontotemporal dementia and neuro inflammation. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Celgene Corporation to develop new therapies for a range of neurodegenerative diseases. Prothena Corporation plc was incorporated in 2012 and is headquartered in Dún Laoghaire, Ireland.

Receive PRTA News and Ratings via Email

Sign-up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:PRTA


Current Ratio19.34
Quick Ratio19.34


Sales & Book Value

Annual Sales$27.52 million
Price / Sales17.61
Price / Cash FlowN/A
Book Value$10.59 per share
Price / Book1.15


Net Income$-153,230,000.00
Net Margins-18,276.97%
Return on Assets-29.80%


Market Cap$479.96 million

Prothena (NASDAQ:PRTA) Frequently Asked Questions

What is Prothena's stock symbol?

Prothena trades on the NASDAQ under the ticker symbol "PRTA."

How were Prothena's earnings last quarter?

Prothena Co. PLC (NASDAQ:PRTA) released its quarterly earnings data on Tuesday, November, 6th. The biotechnology company reported ($0.62) EPS for the quarter, beating analysts' consensus estimates of ($1.05) by $0.43. The biotechnology company had revenue of $0.26 million for the quarter, compared to analysts' expectations of $0.26 million. Prothena had a negative return on equity of 43.17% and a negative net margin of 18,276.97%. View Prothena's Earnings History.

When is Prothena's next earnings date?

Prothena is scheduled to release their next quarterly earnings announcement on Wednesday, February 13th 2019. View Earnings Estimates for Prothena.

What price target have analysts set for PRTA?

9 analysts have issued 1 year target prices for Prothena's stock. Their predictions range from $12.00 to $87.00. On average, they expect Prothena's stock price to reach $39.00 in the next twelve months. This suggests a possible upside of 219.9% from the stock's current price. View Analyst Price Targets for Prothena.

What is the consensus analysts' recommendation for Prothena?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last year. There are currently 1 sell rating, 5 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Prothena.

What are Wall Street analysts saying about Prothena stock?

Here are some recent quotes from research analysts about Prothena stock:
  • 1. According to Zacks Investment Research, "Prothena's license agreement with Roche for prasinezumab is big positive as it not only boosts Prothena’s pipeline development but also provides it with funds in the form of research reimbursement and milestone payments. The company also entered into an agreement with Celgene to develop its pipeline which should boost investor sentiment given the latter’s expertise. However, Prothena suffered a major setback with the discontinuation of development of lead candidate NEOD001. Moreover, due to disappointing data from a phase Ib study, the company will not advance PRX003 into mid-stage development. Consequently, the company has decided to reduce its workforce by 57%. The lack of promising candidates is a concern. Shares have performed worse than the industry in the last twelve months." (1/11/2019)
  • 2. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating and 12-month PT of $18. With discontinuation of NEOD001 development announced in April (our report here), investors are likely to focus on PRX002/RG7935 development as a treatment for Parkinson’s disease (PD). The company has guided to expectation for data from the Phase 2 PASADENA trial in 2020. Release of pharmacodynamic data from lower-dose cohorts of ATTR amyloidosis treatment PRX004 are anticipated in 2019." (8/8/2018)

Has Prothena been receiving favorable news coverage?

News stories about PRTA stock have trended somewhat negative this week, according to InfoTrie. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Prothena earned a coverage optimism score of -1.6 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near term.

Who are some of Prothena's key competitors?

Who are Prothena's key executives?

Prothena's management team includes the folowing people:
  • Mr. Gene G. Kinney, Pres, CEO & Director (Age 49)
  • Mr. Tran B. Nguyen, CFO & COO (Age 44)
  • Mr. Arthur W. Homan, Chief Legal Officer & Company Sec. (Age 59)
  • Ms. Karin L. Walker, Chief Accounting Officer & Controller (Age 55)
  • Dr. Wagner M. Zago, Chief Scientific Officer (Age 45)

How do I buy shares of Prothena?

Shares of PRTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Prothena's stock price today?

One share of PRTA stock can currently be purchased for approximately $12.19.

How big of a company is Prothena?

Prothena has a market capitalization of $479.96 million and generates $27.52 million in revenue each year. The biotechnology company earns $-153,230,000.00 in net income (profit) each year or ($4.07) on an earnings per share basis. Prothena employs 125 workers across the globe.

What is Prothena's official website?

The official website for Prothena is

How can I contact Prothena?

Prothena's mailing address is ADELPHI PLAZA UPPER GEORGE`S STREET, DUN LAOGHAIRE L2, A96 T927. The biotechnology company can be reached via phone at 011-353-1236-2500 or via email at [email protected]

MarketBeat Community Rating for Prothena (NASDAQ PRTA)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  398 (Vote Outperform)
Underperform Votes:  252 (Vote Underperform)
Total Votes:  650
MarketBeat's community ratings are surveys of what our community members think about Prothena and other stocks. Vote "Outperform" if you believe PRTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/17/2019 by Staff

Featured Article: Compound Interest

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel